Outcome variable | OS > 6 months (n = 73) | OS ≤ 6 months (n = 30) | P-value |
---|---|---|---|
Lesion-to-liver contrast ratio | 68 (38–100) | 81 (26–120) | 0.78 |
Venous percentage attenuation ratio | 110 (101–124) | 108 (100–122) | 0.47 |
Delayed percentage attenuation ratio | 122 (112–131) | 115 (106–121) | 0.04 |
Delayed percentage attenuation ratio ≥ 120 | 38 (52.1%) | 8 (26.7%) | 0.03 |
Outcome variable | OS > 12 months (n = 40) | OS ≤ 12 months (n = 63) | P-value |
Lesion-to-liver contrast ratio | 67 (42–87) | 69 (36–102) | 0.64 |
Venous percentage attenuation ratio | 109 (100–125) | 109 (101–123) | 0.89 |
Delayed percentage attenuation ratio | 122 (111–131) | 117 (110–126) | 0.27 |
Delayed percentage attenuation ratio ≥ 120 | 22 (55.0%) | 24 (38.1%) | 0.11 |
Outcome variable | OS > 18 months (n = 24) | OS ≤ 18 months (n = 79) | P-value |
Lesion-to-liver contrast ratio | 70 (54–105) | 69 (36–100) | 0.59 |
Venous percentage attenuation ratio | 106 (98–118) | 110 (102–123) | 0.26 |
Delayed percentage attenuation ratio | 122 (113–131) | 118 (110–126) | 0.31 |
Delayed percentage attenuation ratio ≥ 120 | 14 (58.3%) | 32 (40.5%) | 0.16 |
Outcome variable | OS > 24 months (n = 12) | OS ≤ 24 months (n = 91) | P-value |
Lesion-to-liver contrast ratio | 72 (60–102) | 69 (36–100) | 0.38 |
Venous percentage attenuation ratio | 100 (97–111) | 110 (102–124) | 0.05 |
Delayed percentage attenuation ratio | 118 (111–131) | 118 (110–128) | 0.94 |
Delayed percentage attenuation ratio ≥ 120 | 6 (50.0%) | 40 (44.0%) | 0.76 |